Skip to main content
Translational Andrology and Urology logoLink to Translational Andrology and Urology
. 2016 Aug;5(4):401. doi: 10.21037/tau.2016.06.08

Ejaculatory dysfunction

Chris G McMahon; FAChSHM
PMCID: PMC5001995  PMID: 27652211

Over the past two decades our understanding of ejaculatory dysfunction has evolved from the initial premise that these conditions were almost exclusively due psychological factors to a new understanding. We now understand that men with lifelong premature ejaculation may have an underlying genetic predisposition to rapid ejaculation and that men with acquired premature ejaculation may have, in addition to a variety of psychorelational factors including global anxiety, sexual performance anxiety and depression, be also suffering comorbid erectile dysfunction, chronic prostatitis and a variety of less common conditions including hyperthyroidism. Interested parties have observed a paradigm shift in the way we classify, define, evaluate, diagnose and treat ejaculatory disorders. Our understanding of these disorders is not as advanced as is our understanding of other sexual dysfunctions particularly erectile dysfunction. However there is a growing awareness and an increased level of interest from clinicians, scientists and industry parties which promises future major advances in the management of these important disorders.

graphic file with name tau-05-04-401-fa.jpg

Chris G. McMahon

Footnotes

Conflicts of Interest: Dr. Mcmahon is a consultant, investigator and speaker for Johnson & Johnson, Janssen Cilag, Menarini, Ixchelsis, Absorption Pharmaceuticals, Neurohealing and Plethora.


Articles from Translational Andrology and Urology are provided here courtesy of AME Publications

RESOURCES